(Q34626238)

3 August 2017

Anthracycline-associated cardiotoxicity in survivors of childhood cancer (English)

1 reference

3 August 2017

1 reference

7

Steven E Lipshultz

1 reference

3 August 2017

Barry H Trachtenberg

1

1 reference

3 August 2017

David C Landy

2

1 reference

3 August 2017

Vivian I Franco

3

1 reference

3 August 2017

Jacqueline M Henkel

4

1 reference

3 August 2017

Elliot J Pearson

5

1 reference

3 August 2017

Tracie L Miller

6

1 reference

3 August 2017

9 January 2011

1 reference

3 August 2017

12

1 reference

inferred from page(s)

published in

Pediatric Cardiology

1 reference

3 August 2017

32

1 reference

3 August 2017

3

1 reference

3 August 2017

342-353

1 reference

https://scigraph.springernature.com/pub.10.1007/s00246-010-9878-3

3 August 2017

0 references

cites work

Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Cardiovascular toxicity caused by cancer treatment: strategies for early detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Doxorubicin Cardiomyopathy: Evaluation by Phonocardiography, Endomyocardial Biopsy, and Cardiac Catheterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Carvedilol as therapy in pediatric heart failure: an initial multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Molecular and cellular mechanisms of anthracycline cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Socie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Anthracycline cardiotoxicity: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Anthracycline-induced cardiotoxicity in children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

The cardiotoxicity of adriamycin and daunomycin in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Use of antioxidant supplements during breast cancer treatment: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Detection and monitoring of cardiotoxicity-what does modern cardiology offer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Doxorubicin-induced apoptosis: implications in cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Antioxidants and cancer therapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Cancer incidence among children and adolescents in the United States, 2001-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Cardiac changes associated with growth hormone therapy among children treated with anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Anthracycline associated cardiotoxicity in survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Long-term survivors of childhood cancers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Characteristics and determinants of adiposity in pediatric cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Chronic health conditions in adult survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Echocardiographic evaluation of children with systemic ventricular dysfunction treated with carvedilol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Carvedilol in children with cardiomyopathy: 3-year experience at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Carvedilol for children and adolescents with heart failure: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Biomarkers of oxidative stress in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

The metabolic syndrome in adult survivors of childhood cancer, a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

'Pragmatic randomized controlled trial of individually prescribed exercise versus usual care in a heterogeneous cancer survivor population': a feasibility study PEACH trial: prescribed exercise after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Trastuzumab and doxorubicin-related cardiotoxicity and the cardioprotective role of exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Doxorubicin-induced persistent oxidative stress to cardiac myocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-010-9878-3

Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer

21 January 2018

1 reference

12 December 2020

Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.

1 reference

12 December 2020

Monitoring for anthracycline cardiotoxicity.

1 reference

12 December 2020

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience

1 reference

12 December 2020

Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies

1 reference

12 December 2020

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

1 reference

12 December 2020

Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer

1 reference

12 December 2020

Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer

1 reference

12 December 2020

Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane

1 reference

12 December 2020

Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes

1 reference

12 December 2020

Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study

1 reference

12 December 2020

Long-term cause-specific mortality among survivors of childhood cancer

1 reference

12 December 2020

Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin

1 reference

12 December 2020

ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 199

1 reference

12 December 2020

Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine

1 reference

12 December 2020

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

1 reference

12 December 2020

Cardiovascular trials in long-term survivors of childhood cancer

1 reference

12 December 2020

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial

1 reference

12 December 2020

Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol

1 reference

12 December 2020

Cardioprotective interventions for cancer patients receiving anthracyclines

1 reference

12 December 2020

Effect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin

1 reference

12 December 2020

Beta-blockade in adriamycin-induced cardiomyopathy

1 reference

12 December 2020

Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: A prospective study

1 reference

12 December 2020

A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group

1 reference

12 December 2020

10.1007/S00246-010-9878-3

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference